A Review of Samidorphan: A Novel Opioid Antagonist.

Article Details

Citation
Copy to clipboard

Chaudhary AMD, Khan MF, Dhillon SS, Naveed S

A Review of Samidorphan: A Novel Opioid Antagonist.

Cureus. 2019 Jul 15;11(7):e5139. doi: 10.7759/cureus.5139.

PubMed ID
31523568 [ View in PubMed
]
Abstract

Opioid modulators have been explored as a treatment option for psychiatric disorders, but their use has been limited due to their abuse potential. Samidorphan (SAM), a mu-opioid receptor antagonist, has gained interest due to its favorable pharmacokinetic and pharmacodynamic profile. In this review article, six electronic databases including PubMed, PsycINFO, PsycARTICLES, Scopus, Web of Science, and CINAHL were searched to find relevant human studies with a focus on different clinical aspects of SAM. SAM was used in combination with buprenorphine (BUP) to counteract the abuse potential while still maintaining effectiveness in the treatment of depression. The BUP/SAM 2 mg/2mg combination improved depression in patients with major depressive disorder (MDD). SAM's ability to mitigate the weight gain associated with olanzapine (OLZ) has also been explored. Initial studies have shown promising results in some parameters of alcohol-use disorder, while no significant benefit in the treatment of binge-eating disorder has been reported. Somnolence and gastrointestinal side effects were the most commonly observed side effects of SAM.

DrugBank Data that Cites this Article

Drugs